He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. Tenax’s stock price could double or more if the study hits, or sink to cash levels if it fails. AdvertisementAdding to the fun is the crapshoot nature of the study readout. This is a complicated disease, the proposed mechanism by which Tenax’s drug might work is unproven, and data from a prior study were mixed.